Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-Current Deffered Revenue (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 68.36% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, down 68.36%, and an annual FY2024 reading of $12.6 million, down 70.34% over the prior year.
  • Non-Current Deffered Revenue was $4.2 million for Q3 2025 at Arcturus Therapeutics Holdings, down from $8.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $42.5 million in Q4 2023 and bottomed at $4.2 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $15.2 million, with a median of $11.3 million recorded in 2024.
  • The sharpest move saw Non-Current Deffered Revenue skyrocketed 709.25% in 2023, then tumbled 70.34% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $19.9 million in 2021, then rose by 0.7% to $20.1 million in 2022, then skyrocketed by 111.73% to $42.5 million in 2023, then crashed by 70.34% to $12.6 million in 2024, then plummeted by 66.52% to $4.2 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ARCT at $4.2 million in Q3 2025, $8.8 million in Q2 2025, and $9.6 million in Q1 2025.